eClinical Technology and Industy News

Corteria Pharmaceuticals Announces Initiation of Phase 1 Study

Excerpt from the Press Release:

Corteria Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of transformative therapies for heart failure and obesity, have announced the initiation of its Phase 1 study to evaluate the company’s first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist, COR-1167, for the treatment of Worsening Heart Failure (WHF).

COR-1167 is a once-daily subcutaneous CRF2 agonist that has demonstrated substantial protective effects and functional improvement in the heart, vasculature and kidneys in multiple animal models of heart failure. Its unique mechanism of action offers a novel opportunity for treating WHF with the goal of alleviating cardiac congestion by restoring and maintaining stable cardiovascular and renal function.

The Phase 1 trial is a randomised placebo-controlled study with the primary objective of assessing the safety and tolerability of COR-1167 in both healthy volunteers and patients with chronic heart failure.

“The advancement of our lead CRF2 agonist into the clinic is a significant milestone in our mission to bring novel treatments to patients experiencing the debilitating effects of worsening heart failure,” said Philip Janiak, founder and CEO of Corteria Pharmaceuticals.“The preclinical data for COR-1167 is very promising and we are excited to determine its therapeutic potential in patients.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?